Skip to main content
SpringerLink
Log in

Pathological Assessment of Prostate Cancer

  • Living reference work entry
  • First Online:
Urologic Oncology

  • 170 Accesses

Abstract

In the first instance, the diagnostic approach of prostate cancer (PCa) requires histopathological assessment of tumor tissue, and subsequent immunohistochemical analysis, if needed. In part I of this chapter, methods of PCa diagnosis based on differently obtained prostate tissue as well as essential information that have to be reported from pathologists are described. In addition, histomorphological basics for the diagnosis of PCa and, most importantly, features to differentiate PCa from non-neoplastic prostatic lesions are given. One of the most important information provided by pathologists is the current grading of PCa whose morphological basis is described in more detail. Part II summarizes immunohistochemical markers that are frequently used for diagnostic purposes and of potential prognostic value. In part III, the molecular signature of PCa is described by highlighting the most important characteristics of PCa including heterogeneity of primary PCa, genomic lesions affecting androgen receptor signaling and main changes during progression to metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Amin MB, Epstein JI, Ulbright TM, Humphrey PA, Egevad L, Montironi R, Grignon D, Trpkov K, Lopez-Beltran A, Zhou M, Argani P, Delahunt B, et al. Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference. Am J Surg Pathol. 2014;38:1017–22.

    Article  PubMed  Google Scholar 

  • Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, et al. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Eur J Cancer. 2017;81:228–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153:666–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Am J Surg Pathol. 1999;23:918–24.

    Article  CAS  PubMed  Google Scholar 

  • Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T, Rubin MA. The mutational landscape of prostate cancer. Eur Urol. 2013;64:567–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barros-Silva JD, Paulo P, Bakken AC, Cerveira N, Lovf M, Henrique R, Jeronimo C, Lothe RA, Skotheim RI, Teixeira MR. Novel 5′ fusion partners of ETV1 and ETV4 in prostate cancer. Neoplasia. 2013;15:720–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;63:920–6.

    Article  CAS  PubMed  Google Scholar 

  • Beltran H, Antonarakis ES, Morris MJ, Attard G. Emerging molecular biomarkers in advanced prostate cancer: translation to the clinic. Am Soc Clin Oncol Educ Book. 2016;35:131–41.

    Article  PubMed  Google Scholar 

  • Berg KD. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies. Dan Med J. 2016;63(12).

    Google Scholar 

  • Blattner M, Lee DJ, O’Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia. 2014;16:14–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bostrom PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR. Genomic predictors of outcome in prostate cancer. Eur Urol. 2015;68:1033–44.

    Article  CAS  PubMed  Google Scholar 

  • Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell 2015;163:1011–25.

    Google Scholar 

  • Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. ETS rearrangements and prostate cancer initiation. Nature. 2009a;457:E1; discussion E2-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009b;41:619–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Choy B, Pearce SM, Anderson BB, Shalhav AL, Zagaja G, Eggener SE, Paner GP. Prognostic significance of percentage and architectural types of contemporary Gleason pattern 4 prostate cancer in radical prostatectomy. Am J Surg Pathol. 2016;40:1400–6.

    Article  PubMed  Google Scholar 

  • Christian JD, Lamm TC, Morrow JF, Bostwick DG. Corpora amylacea in adenocarcinoma of the prostate: incidence and histology within needle core biopsies. Mod Pathol. 2005;18:36–9.

    Article  CAS  PubMed  Google Scholar 

  • Egevad L, Allsbrook WC, Epstein JI. Current practice of diagnosis and reporting of prostatic intraepithelial neoplasia and glandular atypia among genitourinary pathologists. Mod Pathol. 2006;19:180–5.

    Article  PubMed  Google Scholar 

  • Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol. 1995;26:223–9.

    Article  CAS  PubMed  Google Scholar 

  • Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 1995;45:81–6.

    Article  CAS  PubMed  Google Scholar 

  • Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228–42.

    Article  PubMed  Google Scholar 

  • Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61:1019–24.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ericson KJ, Wenger HC, Rosen AM, Kiriluk KJ, Gerber GS, Paner GP, Eggener SE. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol. 2017;24:8714–20.

    PubMed  Google Scholar 

  • Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JM, Tomlins SA. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. Mod Pathol. 2016;29:157–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Giannico GA, Arnold SA, Gellert LL, Hameed O. New and emerging diagnostic and prognostic immunohistochemical biomarkers in prostate pathology. Adv Anat Pathol. 2017;24:35–44.

    Article  CAS  PubMed  Google Scholar 

  • Goldstein NS, Martinez A, Vicini F, Stromberg J. The histology of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure. Am J Clin Pathol. 1998;110:765–75.

    Article  CAS  PubMed  Google Scholar 

  • Grignon DJ. Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens. Mod Pathol. 2018;31:S96–109.

    Article  PubMed  Google Scholar 

  • Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42:668–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005;22:88–104.

    Article  PubMed  Google Scholar 

  • Hoang LL, Tacha D, Bremer RE, Haas TS, Cheng L. Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma. Appl Immunohistochem Mol Morphol. 2015;23:711–6.

    Article  CAS  PubMed  Google Scholar 

  • Holger Moch PAH, Ulbright TM, Reuter VE, editors. WHO classification of tumours of the urinary S<stem and male genital organs. 4th ed. Lyon: IARC; 2016.

    Google Scholar 

  • Hudson J, Cao D, Vollmer R, Kibel AS, Grewal S, Humphrey PA. Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome. Hum Pathol. 2012;43:974–9.

    Article  PubMed  Google Scholar 

  • Humphrey PA, Kaleem Z, Swanson PE, Vollmer RT. Pseudohyperplastic prostatic adenocarcinoma. Am J Surg Pathol. 1998;22:1239–46.

    Article  CAS  PubMed  Google Scholar 

  • Iczkowski KA, Bostwick DG. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med. 2000;124:98–107.

    CAS  PubMed  Google Scholar 

  • Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol. 1997;21:1489–95.

    Article  CAS  PubMed  Google Scholar 

  • Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, Rosenfeld MG. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science. 2006;312:1798–802.

    Article  CAS  PubMed  Google Scholar 

  • Kaleem Z, Swanson PE, Vollmer RT, Humphrey PA. Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens. Am J Clin Pathol. 1998;109:695–703.

    Article  CAS  PubMed  Google Scholar 

  • Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin V. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A. 2008;105:2105–10.

    Article  PubMed  PubMed Central  Google Scholar 

  • Leone A, Gershman B, Rotker K, Butler C, Fantasia J, Miller A, Afiadata A, Amin A, Zhou A, Jiang Z, Sebo T, Mega A, et al. Atypical small acinar proliferation (ASAP): is a repeat biopsy necessary ASAP? A multi-institutional review. Prostate Cancer Prostatic Dis. 2016;19:68–71.

    Article  CAS  PubMed  Google Scholar 

  • Lin J, Patel SA, Sama AR, Hoffman-Censits JH, Kennedy B, Kilpatrick D, Ye Z, Yang H, Mu Z, Leiby B, Lewis N, Cristofanilli M, et al. A Phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patients with metastatic castration-resistant prostate cancer progressing on abiraterone. Oncologist. 2016;21:1296–7e.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15:559–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lokman U, Erickson AM, Vasarainen H, Rannikko AS, Mirtti T. PTEN loss but not ERG expression in diagnostic biopsies is associated with increased risk of progression and adverse surgical findings in men with prostate cancer on active surveillance. Eur Urol Focus. 2017;pii:S2405–4569.

    Google Scholar 

  • Lotan TL, Gumuskaya B, Rahimi H, Hicks JL, Iwata T, Robinson BD, Epstein JI, De Marzo AM. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2013;26:587–603.

    Article  CAS  PubMed  Google Scholar 

  • Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. Induced chromosomal proximity and gene fusions in prostate cancer. Science. 2009;326:1230.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. 2012;15:283–8.

    Article  CAS  PubMed  Google Scholar 

  • Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Molinie V, Herve JM, Lebret T, Lugagne-Delpon PM, Saporta F, Yonneau L, Botto H, Baglin AC. Value of the antibody cocktail anti p63 + anti p504s for the diagnosis of prostatic cancer. Ann Pathol. 2004;24:6–16.

    Article  PubMed  Google Scholar 

  • Morais CL, Han JS, Gordetsky J, Nagar MS, Anderson AE, Lee S, Hicks JL, Zhou M, Magi-Galluzzi C, Shah RB, Epstein JI, De Marzo AM, et al. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol. 2015;39:169–78.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013;15:1–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355: 84–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Netto GJ, Epstein JI. Widespread high-grade prostatic intraepithelial neoplasia on prostatic needle biopsy: a significant likelihood of subsequently diagnosed adenocarcinoma. Am J Surg Pathol. 2006;30:1184–8.

    Article  PubMed  Google Scholar 

  • Ng VW, Koh M, Tan SY, Tan PH. Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study. Am J Clin Pathol. 2007;127:248–53.

    Article  CAS  PubMed  Google Scholar 

  • Owens CL, Epstein JI, Netto GJ. Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry. Arch Pathol Lab Med. 2007;131:599–603.

    PubMed  Google Scholar 

  • Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16:793–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882–8.

    Article  PubMed  Google Scholar 

  • Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia. 2009;11:804–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111:753–60.

    Article  PubMed  PubMed Central  Google Scholar 

  • Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Queisser A, Hagedorn SA, Braun M, Vogel W, Duensing S, Perner S. Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. Mod Pathol. 2015;28:138–45.

    Article  CAS  PubMed  Google Scholar 

  • Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, Peng L, Zhang Q, Cheng Y, Su H, Zhou X, Zhang J, et al. Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur Urol. 2017;S0302-2838(17)30720-0.

    Google Scholar 

  • Ro JY, Ayala AG, Ordonez NG, Cartwright J Jr, Mackay B. Intraluminal crystalloids in prostatic adenocarcinoma. Immunohistochemical, electron microscopic, and x-ray microanalytic studies. Cancer. 1986;57: 2397–407.

    Article  CAS  PubMed  Google Scholar 

  • Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rubin MA, Demichelis F. The Genomics of Prostate Cancer: emerging understanding with technologic advances. Mod Pathol. 2018;31:S1–11.

    Article  PubMed  Google Scholar 

  • Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. Alpha-Methylacyl coenzyme a racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287:1662–70.

    Article  CAS  PubMed  Google Scholar 

  • Sailer V, Stephan C, Wernert N, Perner S, Jung K, Dietel M, Kristiansen G. Comparison of p40 (DeltaNp63) and p63 expression in prostate tissues – which one is the superior diagnostic marker for basal cells? Histopathology. 2013;63:50–6.

    Article  PubMed  Google Scholar 

  • Shah RB, Tadros Y, Brummell B, Zhou M. The diagnostic use of ERG in resolving an “atypical glands suspicious for cancer” diagnosis in prostate biopsies beyond that provided by basal cell and alpha-methylacyl-CoA-racemase markers. Hum Pathol. 2013;44:786–94.

    Article  CAS  PubMed  Google Scholar 

  • Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med. 2009;133:1568–76.

    PubMed  Google Scholar 

  • Srirangam V, Rai BP, Abroaf A, Agarwal S, Tadtayev S, Foley C, Lane T, Adshead J, Vasdev N. Atypical small acinar proliferation and high grade prostatic intraepithelial neoplasia: should we be concerned? An observational cohort study with a minimum follow-up of 3 years. Curr Urol. 2017;10:199–205.

    Article  PubMed  PubMed Central  Google Scholar 

  • Statz CM, Patterson SE, Mockus SM. mTOR inhibitors in castration-resistant prostate cancer: a systematic review. Target Oncol. 2017;12:47–59.

    Article  PubMed  Google Scholar 

  • Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP Jr, Rabah DM, Eastham JA, Scardino PT. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014;65:675–80.

    Article  PubMed  Google Scholar 

  • Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, et al. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol. 2015;28:446–56.

    Article  PubMed  CAS  Google Scholar 

  • Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, Moch H, Prive GG, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346:85–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tischler V, Fritzsche FR, Gerhardt J, Jager C, Stephan C, Jung K, Dietel M, Moch H, Kristiansen G. Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker. Histopathology. 2010;56:811–5.

    Article  PubMed  Google Scholar 

  • Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.

    Article  CAS  PubMed  Google Scholar 

  • Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008;13:519–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56:275–86.

    Article  CAS  PubMed  Google Scholar 

  • Tosoian JJ, Antonarakis ES. Molecular heterogeneity of localized prostate cancer: more different than alike. Translat Cancer Res. 2017;6:S47–50.

    Article  Google Scholar 

  • Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PG, Amin MB. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med. 2002;126:554–61.

    PubMed  Google Scholar 

  • Verma S, Choyke PL, Eberhardt SC, Oto A, Tempany CM, Turkbey B, Rosenkrantz AB. The current state of MR imaging-targeted biopsy techniques for detection of prostate cancer. Radiology. 2017;285:343–56.

    Article  PubMed  Google Scholar 

  • Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, et al. Molecular subgroup of primary prostate cancer presenting with metastatic biology. Eur Urol. 2017;72:509–18.

    Article  CAS  PubMed  Google Scholar 

  • Yaskiv O, Cao D, Humphrey PA. Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns. Am J Surg Pathol. 2010;34: 556–61.

    Article  PubMed  Google Scholar 

  • Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, Hammel M, Miller DJ, Walden H, Duda DM, Seyedin SN, Hoggard T, Harper JW, et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell. 2009;36:39–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pathology of the University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany

    Sven Perner, Verena Sailer & Anne Offermann

  2. Research Center Borstel, Leibniz Lung Center, Borstel, Germany

    Sven Perner, Verena Sailer & Anne Offermann

Authors
  1. Sven Perner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Verena Sailer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Offermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sven Perner .

Editor information

Editors and Affiliations

  1. Urologie, Univ Lübeck, Lübeck, Schleswig-Holstein, Germany

    Axel Merseburger

  2. Dept. of Urology, University of Regensburg St. Josef Medical Centre, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Martini-Klinik am UKE GmbH, Hamburg, Germany

    Thomas Steuber

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Perner, S., Sailer, V., Offermann, A. (2019). Pathological Assessment of Prostate Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_71-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_71-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation